This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress (VEMOFIT)

This study is enrolling participants by invitation only.
Sponsor:
Collaborators:
Ministry of Health, Malaysia
UMC Utrecht
Information provided by (Responsible Party):
Boon-How Chew, Universiti Putra Malaysia
ClinicalTrials.gov Identifier:
NCT02730078
First received: March 29, 2016
Last updated: April 10, 2017
Last verified: April 2017
  Purpose
The purpose of the clinical trial is to evaluate the effectiveness of a relatively simple and short value-based emotion-focused educational programme in adults with type 2 diabetes (VEMOFIT) on diabetes-related distress, depressive symptoms, illness perception, medication adherence, quality of life, diabetes self-efficacy, self-care and clinical outcomes.

Condition Intervention
Type 2 Diabetes Mellitus Behavioral: VEMOFIT Behavioral: Attention-meetings (AG)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: The Effectiveness of a Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress in Malay Adults With Type 2 Diabetes (VEMOFIT): a Cluster Randomised Controlled Trial

Further study details as provided by Boon-How Chew, Universiti Putra Malaysia:

Primary Outcome Measures:
  • Diabetes-related distress [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measured with the 17-item Diabetes Distress Scale (DDS-17)

  • Diabetes-related distress [ Time Frame: 6-month [T2] ]
    Measured with the 17-item Diabetes Distress Scale (DDS-17)

  • Diabetes-related distress [ Time Frame: 12-month [T3] ]
    Measured with the 17-item Diabetes Distress Scale (DDS-17)


Secondary Outcome Measures:
  • Depression [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measured with the Patient Health Questionnaire (PHQ-9)

  • Depression [ Time Frame: 6-month [T2] ]
    Measured with the Patient Health Questionnaire (PHQ-9)

  • Depression [ Time Frame: 12-month [T3] ]
    Measured with the Patient Health Questionnaire (PHQ-9)

  • Illness perception [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measured with the Brief Illness Perception Questionnaire (BIPQ)

  • Illness perception [ Time Frame: 6-month [T2] ]
    Measured with the Brief Illness Perception Questionnaire (BIPQ)

  • Illness perception [ Time Frame: 12-month [T3] ]
    Measured with the Brief Illness Perception Questionnaire (BIPQ)

  • Quality of life [ Time Frame: 6-month [T2] ]
    Measured with the WHOQOL-BREF

  • Quality of life [ Time Frame: 12-month [T3] ]
    Measured with the WHOQOL-BREF

  • Self-efficacy [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measured by the Diabetes Management Self Efficacy Scale (DMSES)

  • Self-efficacy [ Time Frame: 6-month [T2] ]
    Measured by the Diabetes Management Self Efficacy Scale (DMSES)

  • Self-efficacy [ Time Frame: 12-month [T3] ]
    Measured by the Diabetes Management Self Efficacy Scale (DMSES)

  • Self-care behaviours [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measured with the Diabetes Self-Care Activities (SDSCA) scale

  • Self-care behaviours [ Time Frame: 6-month [T2] ]
    Measured with the Diabetes Self-Care Activities (SDSCA) scale

  • Self-care behaviours [ Time Frame: 12-month [T3] ]
    Measured with the Diabetes Self-Care Activities (SDSCA) scale

  • Positive emotions [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Measure by the Positive Affects subscale of the Center for Epidemiologic Studies Depression Scale (PA-CESD)

  • Positive emotions [ Time Frame: 6-month [T2] ]
    Measure by the Positive Affects subscale of the Center for Epidemiologic Studies Depression Scale (PA-CESD)

  • Positive emotions [ Time Frame: 12-month [T3] ]
    Measure by the Positive Affects subscale of the Center for Epidemiologic Studies Depression Scale (PA-CESD)

  • HbA1c [ Time Frame: 6-week (immediate post-intervention) [T1] ]
  • HbA1c [ Time Frame: 6-month [T2] ]
  • HbA1c [ Time Frame: 12-month [T3] ]
  • Blood pressure [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    systolic and diastolic blood pressure

  • Blood Pressure [ Time Frame: 6-month [T2] ]
    systolic and diastolic blood pressure

  • Blood pressure [ Time Frame: 12-month [T3] ]
    systolic and diastolic blood pressure

  • LDL-cholesterol [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    lipid profiles

  • LDL-cholesterol [ Time Frame: 6-month [T2] ]
    lipid profiles

  • LDL-cholesterol [ Time Frame: 12-month [T3] ]
    lipid profiles


Other Outcome Measures:
  • Health-care utilisation/hospitalisation [ Time Frame: 6-month [T2] ]
    Number of visits to healthcare facilities including hospitalisation, patient's record and diary used in the study

  • Health-care utilisation/hospitalisation [ Time Frame: 12-month [T3] ]
    Number of visits to healthcare facilities including hospitalisation, patient's record and diary used in the study

  • Adverse event [ Time Frame: 6-week (immediate post-intervention) [T1] ]
    Number of hypoglycaemia and extreme negative emotions as recorded in participant's diary

  • Adverse event [ Time Frame: 6-month [T2] ]
    Number of hypoglycaemia and extreme negative emotions as recorded in participant's diary

  • Adverse event [ Time Frame: 12-month [T3] ]
    Number of hypoglycaemia and extreme negative emotions as recorded in participant's diary


Estimated Enrollment: 200
Study Start Date: April 2016
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Attention-meetings (AG)
Attention-control
Behavioral: Attention-meetings (AG)
Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
Experimental: VEMOFIT (VG)
Personal value exploration, disease education, emotional skills and goal setting.
Behavioral: VEMOFIT
The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
Other Name: Value-based emotion-focused educational programme

Detailed Description:
Type 2 diabetes (T2D) patients experience many psychosocial problems related to their diabetes, as well as social- and work-related relationships. These often lead to emotional disorders such as distress, stress, anxiety and depression. Without proper care, these patients use more often negative coping strategies and more frequently expect that their diabetes will negatively affect their future. A cluster randomised controlled trial will be conducted in 10 public health clinics (HC) in Malaysia. These clusters are eligible if they are providing standard diabetes care according to national clinical practice guidelines, not involved in similar trial and having nurses to be trained to deliver the VEMOFIT educational programmes. Pre-stratification by cluster size and geographic areas of the HCs will get randomised five HCs to the VEMOFIT group (VG) and attention-meetings group (AG), respectively.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Malay patients
  • Diagnosed with T2D for at least two years
  • On regular follow-up with at least three visits in the past one year
  • Have diabetes-related distress (mean DDS-17 score ≥ 3)
  • Showing poor disease control (not reaching targets for one of the three biomarkers, namely HbA1c ≥ 8%, blood pressure ≥ 140/90 mmHg and LDL-C > 2.6 mmol/L)

Exclusion Criteria:

  • Patients who are enrolled in other clinical studies
  • Pregnant or lactating
  • Having psychiatric/ psychological disorders that could impair judgments and memory
  • Patients who cannot read or understand English or Malay
  • Patients who scored ≥ 20 on the Patient Health Questionnaire-9 (PHQ-9) that suggest a severe depression
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02730078

Sponsors and Collaborators
Universiti Putra Malaysia
Ministry of Health, Malaysia
UMC Utrecht
Investigators
Principal Investigator: Boon-How Chew, MMed Universiti Putra Malaysia
  More Information

Additional Information:
Publications:
Responsible Party: Boon-How Chew, Associate Professor, Universiti Putra Malaysia
ClinicalTrials.gov Identifier: NCT02730078     History of Changes
Other Study ID Numbers: NMRR- 15-1144-24803
Study First Received: March 29, 2016
Last Updated: April 10, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Anonymous data will be accessible publicly via the figshare.

Keywords provided by Boon-How Chew, Universiti Putra Malaysia:
Mood Disorders
Self Care
Primary Care

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on June 27, 2017